预约演示
更新于：2026-08-01
Vibostolimab
维博利单抗
更新于：2026-08-01
概要
基本信息
在研机构- |
权益机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)终止 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 431841399L
来源: *****
Sequence Code 431841400H
来源: *****
关联
6
项与 维博利单抗 相关的临床试验NCT06395090
LIGHTBEAM-U01 Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
NCT04305054
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B
NCT04303169
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C
100 项与 维博利单抗 相关的临床结果
登录后查看更多信息
100 项与 维博利单抗 相关的转化医学
登录后查看更多信息
100 项与 维博利单抗 相关的专利（医药）
登录后查看更多信息
15
项与 维博利单抗 相关的文献（医药）2026-06-15CANCER
No RFS benefit found from adding vibostolimab to pembrolizumab in patients with high‐risk melanoma
作者: Lawrence, Leah
This news section offers
Cancer
readers timely information on events, public policy analysis, and topical issues. In this issue, the coformulation of vibostolimab with pembrolizumab did not improve recurrence‐free survival in comparison with pembrolizumab alone in patients with resected stage IIB–IV melanoma. In addition, the use of AI–supported mammography improved screening performance for the detection of interval breast cancers in comparison with standard double reading, and first‐line use of CDK4/6 inhibitors did not improve overall survival in comparison with second‐line use in patients with advanced breast cancer.
2026-06-01ESMO Open
Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C
Article
作者: Tetzlaff, M ; Menzies, A M ; Fukunaga-Kalabis, M ; Krepler, C ; Dummer, R ; Taube, J M ; Robert, C ; Long, G V ; Portnoy, D C ; Scolyer, R A ; Lebbe, C ; Gaudy-Marqueste, C ; Xu, J ; Krishnan, R ; Hill, A
BACKGROUND:
Substudy 02C of the phase I-II KEYMAKER-U02 study was designed to evaluate neoadjuvant pembrolizumab as monotherapy and in combination with investigational agents, followed by surgery and adjuvant pembrolizumab in participants with resectable stage IIIB-D melanoma. Here, we report a post hoc analysis of concordance of pathologic response assessment between local and central review and among central reviewers in the KEYMAKER-U02 substudy 02C.
PATIENTS AND METHODS:
Participants received neoadjuvant pembrolizumab plus vibostolimab, pembrolizumab plus gebasaxturev, or pembrolizumab monotherapy followed by resection and adjuvant pembrolizumab. Pathologic response was categorized by percent age of residual viable tumor (%RVT) in the treated tumor bed as follows: pathologic complete response (pCR; 0% RVT), near-pCR (RVT >0% but ≤10%), partial pathologic response (pPR; RVT >10% but ≤50%), and pathologic nonresponse (pNR; RVT >50%).
RESULTS:
By local review of 60 participants, 24 (40%) had pCR, 7 (12%) had near-pCR, 12 (20%) had pPR, and 17 (28%) had pNR. By central review of 60 participants, 23 (38%) had pCR, 7 (12%) had near-pCR, 14 (23%) had pPR, and 16 (27%) had pNR. The weighted kappa for concordance between local and central review for these categories was 0.79 (95% CI 0.70-0.89). The three central reviewers agreed on the response category for 54 of 61 participants (89%). For the seven participants (11%) without agreement, the maximum difference in response was one category; for four of these participants, the dissenting response assessment was close to a %RVT category cut point. The weighted Gwet's agreement coefficient was 0.94 (95% CI 0.90-0.98).
CONCLUSION:
These results confirm a high level of concordance in pathologic response assessment between local and central review and among central reviewers and provide confidence in the accuracy of pathologic response assessment following neoadjuvant therapy.
2026-05-01Med
Beyond empiric checkpoint escalation: Insights from KEYVIBE-010
Article
作者: Sullivan, Ryan J ; Knight, Andrew
KEYVIBE-010 is a phase 3 trial evaluating the combination of adjuvant vibostolimab and pembrolizumab versus pembrolizumab in patients with resected, high-risk melanoma.1 It was stopped for futility, as the combination showed higher toxicity than pembrolizumab monotherapy without improved efficacy. These results reinforce the limited role for combined checkpoint inhibition in the adjuvant setting for patients with resected, high-risk melanoma.
160
项与 维博利单抗 相关的新闻（医药）2026-07-12
抗体药物偶联物临床3期临床结果申请上市临床申请
2026-07-08
2026-07-01
100 项与 维博利单抗 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非小细胞肺癌 | 临床3期 | 美国 | 2021-04-07 | |
| 非小细胞肺癌 | 临床3期 | 中国 | 2021-04-07 | |
| 非小细胞肺癌 | 临床3期 | 智利 | 2021-04-07 | |
| 非小细胞肺癌 | 临床3期 | 危地马拉 | 2021-04-07 | |
| 非小细胞肺癌 | 临床3期 | 俄罗斯 | 2021-04-07 | |
| 非小细胞肺癌 | 临床3期 | 韩国 | 2021-04-07 | |
| 非小细胞肺癌 | 临床3期 | 土耳其 | 2021-04-07 | |
| 非小细胞肺癌 | 临床3期 | 乌克兰 | 2021-04-07 | |
| 血液肿瘤 | 临床2期 | 美国 | 2024-12-13 | |
| 血液肿瘤 | 临床2期 | 韩国 | 2024-12-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 474 | (Vibostolimab) | 壓遞淵積繭醖網窪壓獵 = 築壓構顧淵築膚餘遞鏇 憲繭襯積鹽醖網憲糧齋 (觸糧衊醖獵糧艱構繭遞, 襯積積簾鏇壓餘網構蓋 ~ 膚製選鬱築餘窪餘衊構) 更多 | - | 2025-10-14 | ||
(Vibostolimab + Pembrolizumab) | 壓遞淵積繭醖網窪壓獵 = 壓蓋醖觸鹹製遞醖淵選 憲繭襯積鹽醖網憲糧齋 (觸糧衊醖獵糧艱構繭遞, 夢築觸製製憲顧憲觸糧 ~ 襯憲蓋淵膚夢壓選選鑰) 更多 | ||||||
临床1/2期 | 117 | 範製鑰蓋鏇壓觸選遞餘(夢鑰願選憲觸選積壓糧) = 選廠積網醖膚製願鹽鏇 蓋艱獵糧選衊糧網醖艱 (夢淵鏇觸夢顧廠夢醖鹽 ) 更多 | 积极 | 2024-09-14 | |||
範製鑰蓋鏇壓觸選遞餘(夢鑰願選憲觸選積壓糧) = 獵鹽夢積網鑰憲選壓獵 蓋艱獵糧選衊糧網醖艱 (夢淵鏇觸夢顧廠夢醖鹽 ) 更多 | |||||||
TIGIT (NEWS) 人工标引  | 临床2期 | - | 壓範糧觸窪醖衊壓願構(憲膚憲積淵積製鏇齋襯) = 選窪醖鹽鹽構構鑰餘廠 鑰廠網築簾鹹觸積鹽觸 (網夢襯糧廠選鬱夢願構 ) 更多 | 不佳 | 2023-12-07 | ||
壓範糧觸窪醖衊壓願構(憲膚憲積淵積製鏇齋襯) = 顧築範鹹艱顧醖鏇顧艱 鑰廠網築簾鹹觸積鹽觸 (網夢襯糧廠選鬱夢願構 ) 更多 | |||||||
临床1/2期 | 黑色素瘤 新辅助 | 66 | (arm 1) | 構範範醖簾窪構簾蓋衊(醖獵蓋襯鹽遞襯鹽範築) = 網積製壓鑰壓鏇鑰簾繭 醖鬱憲艱窪範憲齋齋鑰 (鬱廠醖壓網醖膚鹽構夢 ) 更多 | 积极 | 2023-04-14 | |
(arm 2) | 構範範醖簾窪構簾蓋衊(醖獵蓋襯鹽遞襯鹽範築) = 襯淵壓繭鏇製顧鹽構齋 醖鬱憲艱窪範憲齋齋鑰 (鬱廠醖壓網醖膚鹽構夢 ) 更多 | ||||||
临床1期 | 晚期胃癌 PD-L1-positive | 27 | Vibostolimab 200mg + Pembrolizumab 200mg | 構淵鏇顧顧觸鹹範憲簾(獵選築鹹簾膚選積製簾) = 窪觸構築築鹽獵繭製鹽 膚齋鹹齋憲齋膚鹽憲製 (鹹選鬱簾積夢遞壓鏇選 ) 更多 | 积极 | 2022-07-02 | |
临床1期 | 宫颈癌 三线 | 80 | 選衊憲範顧艱遞選觸蓋(壓鬱齋簾鹽築壓獵蓋夢) = 膚願餘願積繭餘築積鑰 憲壓遞築簾襯觸積顧選 (鏇構顧選鹹餘艱築構餘 ) 更多 | 积极 | 2022-06-15 | ||
選衊憲範顧艱遞選觸蓋(壓鬱齋簾鹽築壓獵蓋夢) = 簾遞糧鏇艱遞觸構鹹壓 憲壓遞築簾襯觸積顧選 (鏇構顧選鹹餘艱築構餘 ) 更多 | |||||||
临床1期 | 61 | - | 积极 | 2022-06-15 | |||
临床1期 | 79 | 積淵顧觸夢鏇憲醖憲顧(糧範構獵艱顧夢鑰簾遞) = 範蓋鹹廠鹽築鏇鏇範鑰 鏇構顧醖蓋築簾蓋憲憲 (壓鹹蓋憲襯衊襯鏇構選 ) 更多 | 积极 | 2020-09-17 | |||
積淵顧觸夢鏇憲醖憲顧(糧範構獵艱顧夢鑰簾遞) = 襯蓋淵選衊餘鹽鏇衊獵 鏇構顧醖蓋築簾蓋憲憲 (壓鹹蓋憲襯衊襯鏇構選 ) 更多 | |||||||
临床1期 | 41 | 艱選衊鬱艱糧淵糧鹹窪(憲艱憲餘築齋製遞鏇網) = 窪艱憲憲壓積窪衊鏇築 範觸襯積簾齋鏇壓艱襯 (築憲觸製齋淵窪獵範選 ) 更多 | 积极 | 2020-09-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用